Hearing assessment in newborns. Ms ENT university exam format for 20 marks

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive information from Cummings and Scott-Brown's. Let me compile the full 20-mark university exam answer.

Hearing Assessment in Newborns

[MS ENT University Examination - 20 Marks]

1. INTRODUCTION AND IMPORTANCE (2 marks)

Neonatal hearing loss is one of the most common congenital disorders, occurring in 1-3 per 1,000 newborns in the general population, and nearly double that rate (2-4 per 1,000) in NICU patients. The World Health Organization estimates that 7.5 million children worldwide have clinically significant hearing loss.

Hearing is fundamental to speech and language development. Delayed detection leads directly to poor speech, language, and cognitive outcomes. Studies have shown that earlier detection leads to earlier intervention and significantly better outcomes - the age of identification dropped from 9 months to 3.5 months, and age at amplification from 13.3 to 5.7 months after universal screening programs were introduced.

The guiding principle is the "1-3-6" rule (Joint Committee on Infant Hearing / EHDI program):

Screen by 1 month of age
Audiometric evaluation by 3 months for those who "refer"
Intervention initiated by 6 months for confirmed permanent hearing loss

2. EPIDEMIOLOGY AND RISK FACTORS (2 marks)

Prior to universal newborn hearing screening (NHS), targeted (high-risk) screening detected at most 50% of affected infants. Only ~3% of US infants were screened before universal programs began.

Risk Indicators for Permanent/Delayed-Onset Hearing Loss (JCIH / AAP Box):

Category	Specific Risk Factors
Family	Family history of permanent childhood hearing loss
NICU	NICU stay >5 days; ECMO; assisted ventilation; ototoxic medications; loop diuretics; hyperbilirubinemia requiring exchange transfusion
Infections	In utero TORCH: toxoplasmosis, rubella, CMV, herpes, syphilis; postnatal culture-positive infections causing SNHL
Structural	Craniofacial anomalies - pinna, ear canal, ear tags, ear pits, temporal bone anomalies
Syndromes	Any syndrome associated with SNHL or permanent CHL (e.g. Waardenburg, Down, Branchio-oto-renal)
Neurological	Neurodegenerative disorders
Trauma/Drugs	Head trauma (basal skull/temporal bone fracture); chemotherapy
Parental concern	Caregiver concern about speech, language, or developmental delay

High-risk children should receive repeat hearing evaluation at 24-30 months even if they pass the newborn screen.

3. SCREENING METHODS (6 marks)

Objective testing is mandatory because newborns cannot participate in behavioral testing. Two objective methods are used:

A. Evoked Otoacoustic Emissions (EOAEs)

OAEs reflect the activity of outer hair cells (OHCs) of the cochlea. OHCs generate energy (cochlear amplifier) that exits through the middle ear and tympanic membrane and is captured in the external auditory canal.

i. Transient Evoked OAE (TEOAE):

A small probe/microphone is placed in the external auditory canal
Clicks at ~80 dB SPL are delivered
Presence of emissions indicates cochlear sensitivity of 20-40 dB HL or better in the range of 500-4000 Hz
Quick, low cost, minimal invasiveness
Referral rate: 5.8%-33% (first screen), 1-6% (second screen)

ii. Distortion Product OAE (DPOAE):

Two pure-tone stimuli f1 and f2 are presented at moderate levels (55-65 dB SPL)
The cochlea generates a distortion product at the frequency 2f1 - f2
Evaluates frequency-specific OHC function

Limitations of OAE:

Affected by middle ear effusion, cerumen, or debris in the outer ear
Cannot detect auditory neuropathy spectrum disorder (ANSD) - will show a false pass (OAEs present but neural pathway abnormal)
Higher referral and false-positive rates compared to AABR

B. Automated Auditory Brainstem Response (AABR)

Transient acoustic stimuli (clicks) at 30-45 dB HL are presented via a probe in the ear canal
Surface electrodes placed at vertex and mastoid region record neural responses
Measures the brainstem neural response to sound - not just outer hair cells
Automated algorithms give a pass or refer result (no subjective interpretation needed)
Lower referral rate: 0.8%-4.9%
More time consuming and costly; requires quieter conditions

Advantages:

Not affected by middle ear fluid (as significantly as OAE)
Can detect auditory neuropathy - therefore is the method of choice in NICU/SCBU infants

C. Comparison Table

Parameter	OAE	AABR
What it tests	Outer hair cells (cochlea)	Brainstem neural pathway
Referral rate (1st screen)	5.8-33%	0.8-9.1%
Referral rate (2nd screen)	1-6%	0.32-4.9%
Cost	Lower	Higher
Speed	Fast	Slower
Middle ear effect	Significantly affected	Minimal effect
Detects auditory neuropathy	No (false pass)	Yes
Technique	Easier	More demanding

4. SCREENING PROTOCOLS (3 marks)

Two-Stage Protocol (most widely used):

Well babies:

Stage 1: TEOAE (up to 2 attempts) in both ears
If Stage 1 refers: Stage 2: AABR
Pass criteria: Pass in both ears on OAE, or pass in both ears on AABR

NICU/SCBU babies (>48 hours in unit):

Both TEOAE AND AABR are performed
Fail AABR in either ear = screen referral → direct audiological assessment
Pass AABR both ears + fail OAE both ears = risk-factor group → follow-up at 8 months
Rationale: ANSD is predominantly found in NICU population; OAE alone would miss it

Timing:

First screen: at least 12 hours after birth, preferably close to discharge (amniotic fluid in the ear canal causes false positives if tested too early)
Rescreening: at 24-48 hours significantly decreases false-positive rates
If first screen refers: repeat screen before diagnostic testing
If child passes NHS: no further testing until age 4 years (except high-risk children)

5. DIAGNOSTIC TESTING (2 marks)

A child who "refers" on two screens is referred for full audiological assessment. This includes:

Diagnostic ABR (click and tone-burst): Gold standard for estimating threshold in infants; no sedation needed under 6 months, sedation may be needed after
OAE testing: To assess outer hair cell function and differentiate ANSD
Tympanometry: To detect middle ear effusion (OME)
Behavioral audiometry: Visual Reinforcement Audiometry (VRA) from ~6 months; Conditioned Play Audiometry from ~2.5 years

Role of OME in Failed Screens:

OME is found in 55-65% of infants who fail the newborn screen
However, presence of OME does NOT rule out underlying SNHL
Management: allow 3 months for resolution; if fluid persists, tympanostomy tubes; then repeat OAE/ABR

Auditory Neuropathy Spectrum Disorder (ANSD):

OAEs present (OHCs normal) but ABR absent/abnormal
Must use ABR (not OAE alone) in high-risk neonates to detect ANSD
Common causes in neonates: hyperbilirubinemia, prematurity, genetic mutations (GJB2/connexin 26, DFNB59/pejvakin)
Key point: ABR abnormalities from hyperbilirubinemia may improve in the first year of life

6. FOLLOW-UP AND INTERVENTION (2 marks)

The complete pathway once hearing loss is confirmed:

Etiology workup - CMV testing (most common congenital viral cause; 0.5-1.7% of all newborns; hearing loss in up to 75% of symptomatic cCMV), gene panel (connexin 26/GJB2 mutation - most common genetic cause), temporal bone imaging (CT/MRI)
Amplification - Hearing aids fitted ideally by 6 months
Early intervention - Speech-language therapy, special education, family counseling
Cochlear implantation - For profound bilateral SNHL not benefiting from hearing aids; typically from 12 months of age

7. BEHAVIORAL TESTS IN OLDER INFANTS (supplementary, 1 mark)

Age	Test
0-6 months	Behavioral Observation Audiometry (BOA) - crude, unreliable
6 months - 2.5 years	Visual Reinforcement Audiometry (VRA)
2.5 - 5 years	Conditioned Play Audiometry (CPA)
>5 years	Pure Tone Audiometry (PTA)

8. KEY SUMMARY POINTS (1 mark)

Incidence of neonatal hearing loss: 1-3/1000 (well babies), 2-4/1000 (NICU)
The "1-3-6" rule is the cornerstone of EHDI programs
OAE tests outer hair cells; AABR tests the brainstem neural pathway
AABR is mandatory in NICU babies - OAE alone misses auditory neuropathy
Two-stage protocols (OAE then AABR) minimize false positives and referral rates
False-positive rates have dropped from 6-10% to 1-2% with improved protocols
CMV is the most common congenital infection causing hearing loss; connexin 26 is the most common genetic cause
Presence of OME does not exclude SNHL - diagnostic ABR must still be performed

Sources: Cummings Otolaryngology Head and Neck Surgery (Chapter 193); Scott-Brown's Otorhinolaryngology Head & Neck Surgery Vol. 2

This is a shared conversation. Sign in to Orris to start your own chat.